Natural substrates and inhibitors of mannan-binding lectin-associated serine protease-1 and-2:: A study on recombinant catalytic fragments

被引:175
作者
Ambrus, G
Gál, P
Kojima, M
Szilágyi, K
Balczer, J
Antal, J
Gráf, L
Laich, A
Moffatt, BE
Schwaeble, W
Sim, RB
Závodszky, P
机构
[1] Hungarian Acad Sci, Inst Enzymol, Biol Res Ctr, H-1113 Budapest, Hungary
[2] Univ Oxford, MRC, Immunochem Unit, Dept Biochem, Oxford, England
[3] Agr Biotechnol Ctr, Anal Synthesis Ctr, H-2101 Godollo, Hungary
[4] Eotvos Lorand Univ, Dept Biochem, Budapest, Hungary
[5] Univ Leicester, Dept Microbiol & Immunol, Leicester, Leics, England
关键词
D O I
10.4049/jimmunol.170.3.1374
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Mannan-binding lectin-associated serine protease (SP) (MASP)-1 and MASP-2 are modular SP and form complexes with mannan-binding lectin, the recognition molecule of the lectin pathway of the complement system. To characterize the enzymatic properties of these proteases we expressed their catalytic region, the C-terminal three domains, in Escherichia coli. Both enzymes autoactivated and cleaved synthetic oligopeptide substrates. In a competing oligopeptide substrate library assay, MASP-I showed extreme Arg selectivity, whereas MASP-2 exhibited a less restricted, trypsin-like specificity. The enzymatic assays with complement components showed that cleavage of intact C3 by MASP-1 and MASP-2 was detectable, but was only similar to0.1% of the previously reported efficiency of C3bBb, the alternative pathway C3-convertase. Both enzymes cleaved CM 10- to 20-fold faster, but still at only similar to1% of the efficiency of MASP-2 cleavage of C2. We believe that C3 is not the natural substrate of either enzyme. MASP-2 cleaved C2 and C4 at high rates. To determine the role of the individual domains in the catalytic region of MASP-2, the second complement control protein module together with the SP module and the SP module were also expressed and characterized. We demonstrated that the SP domain alone can autoactivate and cleave C2 as efficiently as the entire catalytic region, while the second complement control protein module is necessary for efficient C4 cleavage. This behavior strongly resembles C1s. Each MASP-1 and MASP-2 fragment reacted with Cl-inhibitor, which completely blocked the. enzymatic action of the enzymes. Nevertheless, relative rates of reaction with alpha-2-macroglobulin and C1-inhibitor suggest that alpha-2-macroglobulin may be a significant physiological inhibitor of MASP-1.
引用
收藏
页码:1374 / 1382
页数:9
相关论文
共 63 条
[1]   Specificity assay of serine proteinases by reverse-phase high-performance liquid chromatography analysis of competing oligopeptide substrate library [J].
Antal, J ;
Pál, G ;
Asbóth, B ;
Buzás, Z ;
Patthy, A ;
Gráf, L .
ANALYTICAL BIOCHEMISTRY, 2001, 288 (02) :156-167
[2]   MOLECULAR CHARACTERIZATION OF THE CATALYTIC DOMAINS OF HUMAN-COMPLEMENT SERINE PROTEASE BAR CLR [J].
ARLAUD, GJ ;
GAGNON, J ;
VILLIERS, CL ;
COLOMB, MG .
BIOCHEMISTRY, 1986, 25 (18) :5177-5182
[3]  
AULAK KS, 1993, BEHRING I MITT, V93, P204
[4]   THE MOLECULAR EVOLUTION OF GENES AND PROTEINS - A TALE OF 2 SERINES [J].
BRENNER, S .
NATURE, 1988, 334 (6182) :528-530
[5]   The crystal structure of the zymogen catalytic domain of complement protease C1r reveals that a disruptive mechanical stress is required to trigger activation of the C1 complex [J].
Budayova-Spano, M ;
Lacroix, M ;
Thielens, NM ;
Arlaud, GJ ;
Fontecilla-Camps, JC ;
Gaboriaud, C .
EMBO JOURNAL, 2002, 21 (03) :231-239
[6]   Stoichiometry of complexes between mannose-binding protein and its associated serine proteases - Defining functional units for complement activation [J].
Chen, CB ;
Wallis, R .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (28) :25894-25902
[7]   ENZYMATIC-ACTIVITY OF 2ND COMPONENT OF COMPLEMENT [J].
COOPER, NR .
BIOCHEMISTRY, 1975, 14 (19) :4245-4251
[8]   MASP-3 and its association with distinct complexes of the mannan-binding lectin complement activation pathway [J].
Dahl, MR ;
Thiel, S ;
Matsushita, M ;
Fujita, T ;
Willis, AC ;
Christensen, T ;
Vorup-Jensen, T ;
Jensenius, JC .
IMMUNITY, 2001, 15 (01) :127-135
[9]  
DODDS AW, 1993, METHOD ENZYMOL, V223, P46
[10]  
Endo Y, 1998, J IMMUNOL, V161, P4924